Press Releases

First-in-class pharmacological inhibitors of the EBNA1 viral protein are effective at inhibiting tumor growth in preclinical models.

Philadelphia and San Jose, Calif. – (Feb. 21, 2019) – The Wistar Institute has extended its collaboration with Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body’s immune system to fight cancer. The project is focused on understanding the role of myeloid-derived suppressor cells (MDSCs) and how they can be used in diagnostic and therapeutic applications—work advanced by Dmitry I.

Increased NAD+ metabolism promotes cancer progression in a preclinical model of pancreatic cancer through increased secretion of senescence-associated proinflammatory molecules.

Honor recognizes Weiner’s major contributions to the field of synthetic DNA technology.

PHILADELPHIA — (Feb. 14, 2019) — The Wistar Institute was awarded two grants totaling more than $128,000 from the Pennsylvania Department of Labor & Industry to support the Institute’s training and workforce development initiatives in biomedical research.